Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.

Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP.

J Am Soc Nephrol. 2007 Jun;18(6):1889-98. Epub 2007 May 9.

2.

Efficacy and safety of benazepril for advanced chronic renal insufficiency.

Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW.

N Engl J Med. 2006 Jan 12;354(2):131-40.

3.

Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.

Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.

Scand J Urol Nephrol. 2005;39(6):511-7.

PMID:
16303729
4.

High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.

Xie D, Hou FF, Fu BL, Zhang X, Liang M.

J Clin Pharmacol. 2011 Jul;51(7):1025-34. doi: 10.1177/0091270010377502. Epub 2010 Oct 26.

PMID:
20978279
5.

Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis.

Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B.

Am J Kidney Dis. 2004 Feb;43(2):260-8.

PMID:
14750091
6.

Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.

Esnault VL, Ekhlas A, Nguyen JM, Moranne O.

Nephrol Dial Transplant. 2010 Jul;25(7):2218-24. doi: 10.1093/ndt/gfp776. Epub 2010 Jan 26.

PMID:
20106824
7.

Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.

Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Marín R, Campistol JM.

Nephrol Dial Transplant. 2003 Sep;18(9):1806-13.

PMID:
12937228
8.

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D.

Am J Kidney Dis. 2001 Dec;38(6):1381-4.

PMID:
11728979
9.

ATRA therapy restores normal renal function and renal reserve and prevents renal failure.

Woo KT, Lau YK, Chan CM, Wong KS.

Ann Acad Med Singapore. 2005 Jan;34(1):52-9.

10.

Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.

Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE.

J Pediatr. 2003 Jul;143(1):89-97.

PMID:
12915830
11.

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM; RENAAL Study Group..

J Am Soc Nephrol. 2004 Dec;15(12):3117-25.

12.

Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.

Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szydłowska W.

Med Sci Monit. 2005 Apr;11(4):PI31-7. Epub 2005 Mar 24.

PMID:
15795705
13.

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.

Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Danish.

PMID:
11601117
14.

Strict blood-pressure control and progression of renal failure in children.

ESCAPE Trial Group., Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F.

N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.

15.

Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.

Tylicki L, Rutkowski P, Renke M, Rutkowski B.

Am J Nephrol. 2002 Jul-Aug;22(4):356-62.

PMID:
12169868
16.

Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.

Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.

Hypertens Res. 2004 Dec;27(12):963-70.

17.

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

Clin Exp Nephrol. 2006 Sep;10(3):193-200.

PMID:
17009077
18.

Antiproteinuric effects of enalapril and losartan: a pilot study.

White CT, Macpherson CF, Hurley RM, Matsell DG.

Pediatr Nephrol. 2003 Oct;18(10):1038-43. Epub 2003 Aug 12.

PMID:
12920631
19.

Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.

Ellis D, Moritz ML, Vats A, Janosky JE.

Am J Hypertens. 2004 Oct;17(10):928-35.

PMID:
15485756
20.

IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.

Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T.

J Am Soc Nephrol. 2007 Jun;18(6):1880-8. Epub 2007 May 18.

Supplemental Content

Support Center